UK pharmaceutical giant turns to US firm as it buys kidney disease treatment maker ZS Pharma amid booming M&A market
November 09, 2015 at 12:33 AM
1 minute read
The original version of this story was published on Legalweek
Simpson Thacher & Bartlett and David Polk & Wardell have landed the lead roles on UK pharmaceutical giant AstraZeneca’s purchase of US company ZS Pharma for $2.7bn (£1.8bn).
ZS Pharma, which makes a treatment for chronic kidney disease and heart failure, will sell all its shares for $90 each in cash to AstraZeneca, under the terms of the deal.
Presented by BigVoodoo
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Celebrating achievement, excellence, and innovation in the legal profession in the UK.
Our client, a thriving personal injury firm known for its commitment to compassionate client care is seeking an attorney with 5+ years of ex...
McCarter and English s Chambers-ranked Government Contracts group is seeking an experienced, diligent, and proactive government contracts as...
The Court of Appeal, First Appellate District in San Francisco is accepting applications for a central staff attorney vacancy. A regular ful...
